Hematological Malignancies

BCL-2 Inhibition Bcl-2 highly expressed in FL GDC-0199 oral active Bcl-2 inhibitor Phase I dose escalation 200-900 mg cohorts N=44 with NHL FL =11 (26%)

Nausea (34%), diarrhoea (25%), fatigue (21%) Tumour lysis in 1 patient each with DLBCL and MCL 3/11 responses in FL

GDC-0199